Maxigen Biotech Inc (1783) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Maxigen Biotech Inc (1783) has a cash flow conversion efficiency ratio of 0.050x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$74.75 Million ≈ $2.36 Million USD) by net assets (NT$1.50 Billion ≈ $47.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Maxigen Biotech Inc market cap and net worth for the company's overall valuation and market capitalisation.
Maxigen Biotech Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Maxigen Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Maxigen Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Maxigen Biotech Inc ranked by their cash flow conversion efficiency. Explore Maxigen Biotech Inc (1783) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MagnaChip Semiconductor
NYSE:MX
|
-0.020x |
|
Renascor Resources Ltd
AU:RNU
|
0.003x |
|
UNICOMMERCE ESOLUTIONS LIMITED
NSE:UNIECOM
|
0.154x |
|
Merck Tbk
JK:MERK
|
0.165x |
|
Tait Marketing & Distribution Co Ltd
TWO:5902
|
0.062x |
|
TMT Investments PLC
LSE:TMT
|
-0.003x |
|
Patriot National Bancorp Inc
NASDAQ:PNBK
|
-0.063x |
|
Christiani & Nielsen (Thai) Public Company Limited
BK:CNT
|
0.160x |
Annual Cash Flow Conversion Efficiency for Maxigen Biotech Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Maxigen Biotech Inc from 2009 to 2025. View Maxigen Biotech Inc (1783) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.54 Billion ≈ $48.44 Million |
NT$290.22 Million ≈ $9.14 Million |
0.189x | -12.97% |
| 2024-12-31 | NT$1.38 Billion ≈ $43.32 Million |
NT$298.22 Million ≈ $9.40 Million |
0.217x | +72.42% |
| 2023-12-31 | NT$1.36 Billion ≈ $42.88 Million |
NT$171.20 Million ≈ $5.39 Million |
0.126x | -39.27% |
| 2022-12-31 | NT$1.30 Billion ≈ $40.82 Million |
NT$268.34 Million ≈ $8.45 Million |
0.207x | +101.08% |
| 2021-12-31 | NT$1.14 Billion ≈ $35.97 Million |
NT$117.59 Million ≈ $3.70 Million |
0.103x | +19.10% |
| 2020-12-31 | NT$860.23 Million ≈ $27.10 Million |
NT$74.39 Million ≈ $2.34 Million |
0.086x | -22.02% |
| 2019-12-31 | NT$851.32 Million ≈ $26.82 Million |
NT$94.42 Million ≈ $2.97 Million |
0.111x | -45.19% |
| 2018-12-31 | NT$842.98 Million ≈ $26.56 Million |
NT$170.58 Million ≈ $5.37 Million |
0.202x | +291.31% |
| 2017-12-31 | NT$796.25 Million ≈ $25.09 Million |
NT$41.18 Million ≈ $1.30 Million |
0.052x | +16.39% |
| 2016-12-31 | NT$781.38 Million ≈ $24.62 Million |
NT$34.72 Million ≈ $1.09 Million |
0.044x | +133.57% |
| 2015-12-31 | NT$829.86 Million ≈ $26.14 Million |
NT$-109.85 Million ≈ $-3.46 Million |
-0.132x | -703.35% |
| 2014-12-31 | NT$877.01 Million ≈ $27.63 Million |
NT$-14.45 Million ≈ $-455.29K |
-0.016x | +34.46% |
| 2013-12-31 | NT$888.39 Million ≈ $27.99 Million |
NT$-22.34 Million ≈ $-703.71K |
-0.025x | -155.33% |
| 2012-12-31 | NT$385.66 Million ≈ $12.15 Million |
NT$17.53 Million ≈ $552.17K |
0.045x | +121.89% |
| 2011-12-31 | NT$369.25 Million ≈ $11.63 Million |
NT$-76.64 Million ≈ $-2.41 Million |
-0.208x | -389.53% |
| 2010-12-31 | NT$395.39 Million ≈ $12.46 Million |
NT$-16.76 Million ≈ $-528.16K |
-0.042x | -168.87% |
| 2009-12-31 | NT$313.03 Million ≈ $9.86 Million |
NT$19.27 Million ≈ $607.14K |
0.062x | -- |
About Maxigen Biotech Inc
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, d… Read more